Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia

Br J Haematol. 2022 Aug;198(4):790-793. doi: 10.1111/bjh.18306. Epub 2022 Jun 14.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Australia / epidemiology
  • Duration of Therapy
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Piperidines / therapeutic use

Substances

  • Piperidines
  • ibrutinib
  • Adenine